ADC Therapeutics

About ADC Therapeutics

ADC Therapeutics is a leading antibody drug conjugate company focused on transforming the lives of those impacted by cancer through innovative science and inspiring hope. Their mission is centered on developing targeted therapies to improve patient outcomes.

Products & Services

ZYNLONTA (loncastuximab tesirine-lpyl):A targeted therapy for the treatment of certain types of cancer, specifically relapsed or refractory diffuse large B-cell lymphoma.

Pipeline Products:Includes loncastuximab tesirine-lpyl and ADCT-602, which are under development for various cancer indications.

Specialties

Antibody Drug Conjugates (ADCs) Cancer Treatment Oncology Research

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: PIPE T: - FT: PIPE	A: 60000000 MR: - FA: 60.0 million FAN: 60000000	D: 2025-10-13 FD: 2025-10-13	2 investors
2	RT: PIPE T: - FT: PIPE	A: 100000000 MR: - FA: $100.0 million FAN: 100000000	D: 2025-06-12 FD: 2025-06-12	1 investors
3	RT: Underwritten Offering T: - FT: Underwritten Offering	A: 105000000 MR: - FA: 105.0 million FAN: 105000000	D: 2024-05-06 FD: 2024-05-06	3 investors
4	RT: Underwritten Offering T: - FT: Underwritten Offering	A: 60000000 MR: - FA: $60,000,000 FAN: 60000000	D: 2023-02-02 FD: 2023-02-02	4 investors

PIPE Latest

2025-10-13

$60.0M

2 investors (Pro only)

PIPE 2025-06-12

$100.0M

Underwritten Offering 2024-05-06

$105.0M

View 3 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

C

Chris Martin

CEO

R

Ron Squarer

Chairman of the Board

A

Ameet Mallik

CEO

L

Laurél Tasso

Executive Assistant

A

Ana Varela

NJ Office Manager

D

David Gilman

Chief Business & Strategy Officer

View 17 more team members with Pro

Unlock Full Team Directory

Recent News